Chemistry:LY-334370

From HandWiki
Short description: Chemical compound
LY-334370
LY334370.svg
LY-334370 3D BS.png
Names
Preferred IUPAC name
4-Fluoro-N-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]benzamide
Other names
LY-334,370
Identifiers
3D model (JSmol)
ChemSpider
MeSH C108218
UNII
Properties
C21H22FN3O
Molar mass 351.425 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is ☑Y☒N ?)
Infobox references

LY-334370 is a selective 5-HT1F receptor agonist[1] which was under development by Eli Lilly and Company for the treatment of migraine headaches.[2] The drug showed efficacy in a phase II clinical trial[3] but further development was halted due to toxicity detected in animals.[4]

See also

References

  1. "G-protein activation at 5-HT1A receptors by the 5-HT1F ligand LY-334,370 in guinea-pig brain sections and recombinant cell lines". Br. J. Pharmacol. 124 (2): 283–90. 1998. doi:10.1038/sj.bjp.0701832. PMID 9641544. 
  2. "Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY-334,370". Cephalalgia 19 (10): 851–8. 1999. doi:10.1046/j.1468-2982.1999.1910851.x. PMID 10668103. 
  3. "Selective seratonin 1F (5-HT1F) receptor agonist LY334370 for acute migraine: a randomised controlled trial". Lancet 358 (9289): 1230–4. 2001. doi:10.1016/S0140-6736(01)06347-4. PMID 11675061. 
  4. "New and future migraine therapy". Pharmacol. Ther. 112 (1): 199–212. 2006. doi:10.1016/j.pharmthera.2005.04.010. PMID 16797716. 

External links